Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 411.10
Bid: 411.00
Ask: 411.30
Change: 0.60 (0.15%)
Spread: 0.30 (0.073%)
Open: 412.30
High: 414.60
Low: 410.50
Prev. Close: 410.50
RTO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q1 Trading Update

19 Apr 2017 07:00

RNS Number : 6538C
Rentokil Initial PLC
19 April 2017
 

RENTOKIL INITIAL PLC (RTO)

FIRST QUARTER TRADING UPDATE

19 April 2017

 

 

(£m)

Q1 2017

Growth

AER

AER

CER

Ongoing Revenue1

579.0

23.8%

10.0%

Revenue

580.0

22.9%

9.2%

 

Overview (CER)

Ongoing Revenue increased by 10.0% in Q1, of which 3.1% was Organic Revenue2 growth (Q1 2016: 2.8%, FY 2016: 3.0%) and 6.9% was from acquisitions. On 16 December 2016 the Company announced the proposed transfer of its workwear and hygiene businesses in Germany and the Benelux to a joint venture (JV) with Haniel. The transaction remains on track to complete by mid-year, subject to competition clearance. Excluding those businesses transferring to the JV the Organic Revenue growth rate was 3.5%. Pest Control grew by 19.1% (5.6% Organic Revenue growth) while Hygiene revenues rose by 3.7% (3.1% Organic Revenue growth). Ongoing Revenue growth in our Emerging and Growth markets has once again been strong, increasing by 24.5% and 12.6% respectively. Our businesses in Manage for Value markets delivered Ongoing Revenue growth of 2.5% while those in the Protect and Enhance markets delivered in line with last year.

 

There has been continuing strong performance in Asia, Pacific, Latin America, the UK and in our largest market, North America. Europe delivered improved Ongoing Revenue growth in Q1, with revenues in France broadly flat year on year.

 

M&AWe have acquired 12 businesses this year to date, ten in Pest Control, one in Hygiene and one in Property Care, principally in Emerging and Growth markets. Combined annualised revenues of the businesses acquired totalled £101.7m in the 12 months immediately prior to acquisition. 

In February we announced the acquisition of Atlanta-based pest control company Allgood Pest Solutions. The business generated annualised revenues for the 12 months prior to acquisition of $26.6m.

Also, as previously announced, in March we completed the transaction to create a joint venture with PCI Pest Control Pvt. Ltd. (PCI), India's largest pest control company, which offers a comprehensive range of pest control services and products through its countrywide network. Rentokil, which has management control of the JV, is integrating its Indian operations into the JV and the combined business has revenues of 4.5bn rupees (c. £50m), will operate from c. 250 locations and employ c. 6,900 people.

On 11 April our JV in the Kingdom of Saudi Arabia (KSA) acquired Sames, the market leader in the commercial pest control sector in KSA with c. 2,500 customers covering most major cities, making us the number one pest control company in KSA and the Gulf Cooperation Council countries. The business generated revenues of £9m in the last 12 months prior to acquisition.

Commenting on today's announcement Andy Ransom, Chief Executive, said:

"We have made a good start to 2017. Pest Control has performed well across the regions and we remain encouraged by the progress we are continuing to deliver in Hygiene. We have been very active in M&A in the first three months of the year, reinforcing our strategy of acquiring high quality pest control and hygiene businesses in Emerging and Growth markets. We are particularly pleased with our JV with PCI in India, which is an outstanding business in a country with significant growth potential for commercial and residential pest control services.

"We are confident that the Company will deliver a performance in line with expectations for 2017."

Enquiries:

 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

Media:

Malcolm Padley

Rentokil Initial plc

07788 978 199

John Sunnucks

Bell Pottinger

0203 772 2549

 

 

AER - actual exchange rates; CER - constant 2016 exchange rates

 

1Ongoing Revenue represents the performance of the continuing operations of the Group (including acquisitions) after removing the effect of disposed or closed businesses.

 

2Organic Revenue represents the growth in Ongoing Revenue excluding the effect of businesses acquired during the year. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations.

 

This announcement contains statements that are, or may be, forward-looking regarding the group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTMMGMDRRDGNZM
Date   Source Headline
23rd Apr 20249:30 amRNSHolding(s) in Company
18th Apr 20247:00 amRNSQ1 Trading Update
2nd Apr 20241:28 pmRNSBlock listing Interim Review
2nd Apr 202412:17 pmRNSTotal Voting Rights
27th Mar 202410:23 amRNSAnnual Financial Report
19th Mar 20242:05 pmRNSAdditional Listing
14th Mar 202410:19 amRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSFinal Results
1st Dec 20237:00 amRNSNorth American Management Changes
10th Nov 20232:28 pmRNSDirector/PDMR Shareholding
3rd Nov 20234:26 pmRNSHolding(s) in Company
3rd Nov 20234:22 pmRNSDirector/PDMR Shareholding
1st Nov 202312:50 pmRNSHolding(s) in Company
31st Oct 202311:45 amRNSHolding(s) in Company
30th Oct 20233:03 pmRNSDirector/PDMR Shareholding
30th Oct 202311:55 amRNSCredit rating update
19th Oct 20237:00 amRNSQ3 Trading Update
2nd Oct 202311:35 amRNSBlock listing Interim Review
27th Sep 20232:35 pmRNSDirector/PDMR Shareholding
1st Aug 202312:42 pmRNSDirector/PDMR Shareholding
27th Jul 20237:00 amRNS2023 Interim Results
29th Jun 20239:00 amRNSNotice of Management Presentation
23rd Jun 20235:58 pmRNSDirector/PDMR Shareholding
19th May 20233:03 pmRNSDirector/PDMR Shareholding
12th May 20239:09 amRNSDirector/PDMR Shareholding
11th May 20239:17 amRNSResult of AGM
28th Apr 202310:55 amRNSHolding(s) in Company
21st Apr 20232:41 pmRNSDirector/PDMR Shareholding
20th Apr 20237:00 amRNSQ1 Trading Update
4th Apr 20239:37 amRNSAnnual Financial Report
3rd Apr 202310:08 amRNSBlock listing Interim Review
23rd Mar 20239:42 amRNSDirector/PDMR Shareholding
20th Mar 20234:47 pmRNSDirector/PDMR Shareholding
16th Mar 20237:05 amRNSDirectorate Change
16th Mar 20237:00 amRNSFinal Results
9th Mar 20239:23 amRNSDirector Declaration
27th Feb 20238:55 amRNSNotice of Management Presentation
9th Nov 20224:33 pmRNSDirector Declaration
1st Nov 20222:25 pmRNSCorrection: Q3 Trading Update
1st Nov 20227:00 amRNSQ3 Trading Update
31st Oct 20224:03 pmRNSTotal Voting Rights
24th Oct 20225:15 pmRNSHolding(s) in Company
21st Oct 20224:42 pmRNSHolding(s) in Company
20th Oct 202212:35 pmRNSHolding(s) in Company
19th Oct 202211:43 amRNSHolding(s) in Company
18th Oct 20225:22 pmRNSHolding(s) in Company
17th Oct 20226:07 pmRNSHolding(s) in Company
17th Oct 202211:51 amRNSHolding(s) in Company
14th Oct 20224:39 pmRNSHolding(s) in Company
14th Oct 20224:37 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.